特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
927374

医薬品の中国市場:2030年までの予測

The China Pharmaceutical Market to 2030

出版日: | 発行: GMR Data Ltd | ページ情報: 英文 101 Pages; 60 Tables & Figures | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
医薬品の中国市場:2030年までの予測
出版日: 2020年02月29日
発行: GMR Data Ltd
ページ情報: 英文 101 Pages; 60 Tables & Figures
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

中国の医薬品部門は、医療への関心が高い中産階級の増加が国内市場を大きく牽引するため、今後10年間で大幅な成長が見込まれています。

当レポートでは、中国の医薬品市場について調査分析し、概要、促進要因・抑制要因、市場の構造、主要企業などについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 中国の医薬品市場の促進要因・抑制要因

第3章 中国の医療指標 vs. 世界の医療指標

  • 人口統計指標
  • 医療費
  • PE/VC投資
  • 米国からの影響 - 中国の医薬品市場に対する中国の貿易戦争

第4章 中国の医薬品市場の構造

  • 中国の医療制度改革 - 分析
  • 中国の医療制度改革 - 医薬品市場への影響
  • 規制構造
  • 流通構造

第5章 中国の医薬品市場

  • 概要
  • 成長促進要因
  • 障壁/抑制要因
  • 競合情勢
  • 動向と将来の見通し

第6章 中国の医薬品市場:種類別

  • 中国の低分子医薬品市場
  • 中国の生物製剤市場

第7章 中国のAPI市場

第8章 中国の医薬品市場:主要治療薬別

  • 心血管薬
  • 抗感染症薬
  • がん治療薬
  • 糖尿病治療薬

第9章 企業プロファイル

  • SINO BIOPHARMACEUTICAL LTD.
  • CSPC PHARMACEUTICAL GROUP LTD.
  • ASTRAZENECA CHINA
  • PFIZER CHINA
  • SHANGHAI PHARMACEUTICALS HOLDING COMPANY LTD.
  • FOSUN PHARMA
目次
Product Code: CHIPHARM2030

Features:

  • Increase your foothold in the Chinese market TODAY
  • Establish partnerships to manufacture, distribute or develop Chinese products
  • Scope out the market prior to entry

This new GMR Data report covers the length and breadth of the China Pharmaceutical sector. Every news service globally is focused on COVID-19 (“Coronavirus”) and how it will affect the global population, but what of the China health system itself? How does the sector operate during ‘normal' times?

What will drive and restrain the Chinese health markets?

  • Increase in Non-Communicable Disease (NCD)
  • Elderly population
  • Expanding Middle Class
  • Governmental Policy / Trade War
  • Industry Harmonization with Global Markets

GMR Data view that the Chinese pharmaceutical sector is set for substantial growth across the next decade as an increasing middle class, which has greater access to healthcare, is set to drive the domestic market significantly. A growing population, which is tilted towards the middle aged and elderly, is another factor that will boost Chinese healthcare and pharmaceutical markets.

China is the largest supplier of raw materials to that produce high-priced, non-generic drugs produced by the US, with an ongoing Trade war Chinese pharmaceuticals face tariffs; this is likely to strengthen the domestic (Chinese) pharmaceutical market in the short to mid-term.

China became a member of the International Council for Harmonization in 2017 and accepted declarations in clinical trials/ approvals by the US FDA and the EMA, shortening clinical trial authorization processes significantly in China.

This GMR Data report is the single tool to equip you with the latest trends in the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.

With over 100 pages, and over 60+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • 1.1. REPORT DESCRIPTION
  • 1.2. MARKET SEGMENTATION
  • 1.3. RESEARCH METHODOLOGY

CHAPTER II: DRIVERS & RESTRAINTS OF THE CHINESE PHARMACEUTICAL MARKET

CHAPTER III: CHINA HEALTHCARE INDICATORS VS GLOBAL HEALTHCARE INDICATORS

  • 3.1. DEMOGRAPHIC INDICATORS
  • 3.2. HEALTHCARE EXPENDITURE
  • 3.3. PRIVATE EQUITY / VENTURE CAPITAL INVESTMENTS
  • 3.4. IMPLICATIONS FROM US - CHINA TRADE WAR ON CHINA PHARMACEUTICAL MARKET
    • 3.4.1. No Impact on Chinese APIs
    • 3.4.2. Adverse Impact on Chinese Outbound Investments, M&As

CHAPTER IV: CHINA PHARMACEUTICAL MARKET STRUCTURE

  • 4.1. HEALTHY CHINA 2020 REFORMS - REVIEW
  • 4.2. HEALTHY CHINA 2030 REFORMS - IMPACT ON PHARMACEUTICAL MARKET
  • 4.3. REGULATORY STRUCTURE
    • 4.3.1. Regulatory Authorities
    • 4.3.2. Current Regulatory Policies for Drugs/Pharmaceuticals
    • 4.3.3. Registration Process / Approval for Domestic and Imported Drugs
    • 4.3.4. Intellectual Property Rights / Patent law
    • 4.3.5. Pricing and Reimbursement
  • 4.4. DISTRIBUTION STRUCTURE
    • 4.4.1. Average Sales Force Size
    • 4.4.2. Bribery Penalties - Indications of Changing Pharmaceutical Distribution Practices
    • 4.4.3. China Hospitals Sales, 2020 - 2030 ($ bn)
    • 4.4.4. China Retail Pharmacies Sales, 2020 - 2030 ($ bn)
    • 4.4.5. China e-Pharmacies Sales, 2020 - 2030 ($ bn)

CHAPTER V: CHINA PHARMACEUTICAL MARKET

  • 5.1. OVERVIEW
  • 5.2. GROWTH DRIVERS
    • 5.2.1. Higher Proportion of Geriatric Population and Increased Incidence of ‘Lifestyle' Diseases
    • 5.2.2. Rising Affordability
    • 5.2.3. Supply-Side Reforms Augment Demand
  • 5.3. BARRIERS / RESTRAINTS
    • 5.3.1. Non-Uniform Reimbursements
    • 5.3.2. Low R&D% Investment
  • 5.4. COMPETITIVE LANDSCAPE
    • 5.4.1. Foreign Companies - Key Operating/High ROI Therapeutic Areas
    • 5.4.2. Domestic Companies - Key Operating/High ROI Therapeutic Areas
  • 5.5. TRENDS AND FUTURE OUTLOOK
    • 5.5.1. Massive in-bound funds flow to spur local R&D/innovation
    • 5.5.2. Reverse brain-drain in China pharmaceutical market
    • 5.5.3. Digital customer engagement becoming the necessary evil

CHAPTER VI: CHINA PHARMACEUTICAL MARKET, BY TYPE, 2020 - 2030 ($ BN)

  • 6.1. CHINA SMALL MOLECULE DRUGS MARKET, 2020 - 2030 ($ BN)
    • 6.1.1. China Patented Small Molecule Drugs Market, 2020 - 2030 ($ bn)
    • 6.1.2. China Generic Small Molecule Drugs Market, 2020 - 2030 ($ bn)
  • 6.2. CHINA BIOLOGICS MARKET, 2020 - 2030 ($ BN)
    • 6.2.1. China Patented Biologics Market, 2020 - 2030 ($ bn)
    • 6.2.2. China Biosimilars Market, 2020 - 2030 ($ bn)
    • 6.2.3. China Vaccines Market, 2020 - 2030 ($ bn)

CHAPTER VII: CHINA APIs MARKET, 2020 - 2030 ($ BN)

CHAPTER VIII: CHINA PHARMACEUTICAL MARKET, BY KEY THERAPEUTICS, 2020 - 2030 ($ BN)

  • 8.1. CHINA CARDIOVASCULAR DRUGS MARKET, 2020 - 2030 ($ BN)
  • 8.2. CHINA ANTI-INFECTIVE DRUGS MARKET, 2020 - 2030 ($ BN)
  • 8.3. CHINA ONCOLOGY DRUGS MARKET, 2020 - 2030 ($ BN)
  • 8.4. CHINA DIABETES DRUGS MARKET, 2020 - 2030 ($ BN)

CHAPTER IX: COMPANY PROFILES

  • 9.1. SINO BIOPHARMACEUTICAL LTD.
    • 9.1.1. Background
    • 9.1.2. Business Structure - China
    • 9.1.3. Products / Services - China
    • 9.1.4. Distribution Network - China
    • 9.1.5. Growth strategy - China
    • 9.1.6. Financial Information - China
  • 9.2. CSPC PHARMACEUTICAL GROUP LTD.
    • 9.2.1. Background
    • 9.2.2. Business Structure - China
    • 9.2.3. Products / Services - China
    • 9.2.4. Distribution Network - China
    • 9.2.5. Growth strategy - China
    • 9.2.6. Financial Information - China
  • 9.3. ASTRAZENECA CHINA
    • 9.3.1. Background
    • 9.3.2. Business Structure - China
    • 9.3.3. Products / Services - China
    • 9.3.4. Distribution Network - China
    • 9.3.5. Growth strategy - China
    • 9.3.6. Financial Information - China
  • 9.4. PFIZER CHINA
    • 9.4.1. Background
    • 9.4.2. Business Structure - China
    • 9.4.3. Products / Services - China
    • 9.4.4. Distribution Network - China
    • 9.4.5. Growth strategy - China
    • 9.4.6. Financial Information - China
  • 9.5. SHANGHAI PHARMACEUTICALS HOLDING COMPANY LTD.
    • 9.5.1. Background
    • 9.5.2. Business Structure - China
    • 9.5.3. Products / Services - China
    • 9.5.4. Distribution Network - China
    • 9.5.5. Growth strategy - China
    • 9.5.6. Financial Information - China
  • 9.6. FOSUN PHARMA
    • 9.6.1. Background
    • 9.6.2. Business Structure - China
    • 9.6.3. Products / Services - China
    • 9.6.4. Distribution Network - China
    • 9.6.5. Growth strategy - China
    • 9.6.6. Financial Information - China
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.